News|Articles|March 13, 2024
Overcoming oncolytic virus therapy production challenges through collaboration
Author(s)ReciBioPharm
Discover how ReciBioPharm’s strategic approach helped to support the rapid delivery of an innovative oncolytic adenovirus therapy for advanced cancer to clinic.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
2
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
3
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
4
High-Dose Nusinersen Slows Neurodegeneration in SMA Patients, Study Shows
5